ClinicalTrials.gg

Triple Negative Breast Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,219 studies for Triple Negative Breast Neoplasms across more than 10 countries. 443 are recruiting or about to start. 857 of them are mainly about Triple Negative Breast Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 1,517 studies for Triple Negative Breast Neoplasms. How that becomes 1,219 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Triple Negative Breast Neoplasms, and those it files under no condition that list Triple Negative Breast Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,517Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −8List Triple Negative Breast Neoplasms as a condition, but the registry did not file them under itMost often written as “Advanced Triple Negative Breast Cancer” (2), “Triple Negative Breast Cancer Patients” (1), and “Advanced, Androgen Receptor Positive Triple Negative Breast Cancer” (1). The registry filed them under other conditions only, most often Breast Neoplasms (4) and Carcinoma, Non-Small-Cell Lung (1).
  3. −290Match it another way201 name it in the title and 89 by a synonym or other text the search reads.
  4. 1,219The count on this page17 of them list Triple Negative Breast Neoplasms in their own words; the registry filed them under no condition.

Status

Recruiting
330
Completed
303
Active, not recruiting
159
Terminated
154
Not yet recruiting
108
Status unknown
91

Phase

Phase 2
616
Phase 1
466
Phase 3
101
Early Phase 1
28
Phase 4
6

Where

United States
645
China
252
Spain
136
France
125
Canada
96
United Kingdom
94

Who develops what

Add Triple Negative Breast Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 63 programs from 53 companies, 36 with this as their studies’ main aim; 13 with a live phase 3 study; 14 primary completions in the next 12 months. Compare Beijing Biotech, Merck and Jiangsu HengRui Medicine here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07762703 · BreakBio Corp · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2026
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07679360 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Pembrolizumab injection” · registered Jun 2026
  • NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2024
  • NCT06249048 · Strand Therapeutics Inc. · Phase 2 · live · background · “Keytruda®” · registered Feb 2024
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)1111 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07544056 · BeBetter Med Inc · Phase 3 · live · background · “Carboplatin Injection” · registered Apr 2026
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Carboplatin” · registered May 2025
  • NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Carboplatin” · registered Apr 2025
  • NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Carboplatin” · registered Feb 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Carboplatin” · registered Feb 2025
Eli Lilly and Company16% of its industry studies1013 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07729956 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Jul 2026
  • NCT07281976 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · background · “albumin-bound Paclitaxel injection” · registered Dec 2025
  • NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Feb 2025
  • NCT06767527 · Akeso · Phase 3 · live · background · “Nab-paclitaxel” · registered Jan 2025
  • NCT06419621 · BioNTech SE · Phase 3 · live · background · “Nab-Paclitaxel” · registered May 2024
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)911 studies
GemcitabineRecent, repeated
Evidence
  • NCT07544056 · BeBetter Med Inc · Phase 3 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Apr 2026
  • NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Mar 2026
  • NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2025
  • NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Gemcitabine” · registered Feb 2025
  • NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Jul 2024
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed910 studies
CapecitabineRecent, repeated
Evidence
  • NCT07679360 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Capecitabine tablets” · registered Jun 2026
  • NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Capecitabine Tablets” · registered Mar 2026
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Capecitabine” · registered May 2025
  • NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Capecitabine” · registered Apr 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Feb 2025
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized911 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07111832 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel for Injection” · registered Aug 2025
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Paclitaxel” · registered May 2025
  • NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Paclitaxel” · registered Apr 2025
  • NCT06841354 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Feb 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Paclitaxel” · registered Feb 2025
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed811 studies
eribulinRecent, repeated
Evidence
  • NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Eribulin” · registered Jul 2024
  • NCT06449222 · BioNTech SE · Phase 2 · live · background · “Eribulin” · registered Jun 2024
  • NCT06279364 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “Eribulin” · registered Feb 2024
  • NCT02555657 · Merck & Co., Inc · Phase 3 · comparator · “eribulin” · registered Sep 2015
Eisai Co., Ltd.87% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 2 generics authorized33 studies
toripalimabRecent, repeated
Evidence
  • NCT07281976 · Nanjing Leads Biolabs Co.,Ltd · Phase 2 · live · comparator · “Toripalimab Injection” · registered Dec 2025
  • NCT07111832 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Toripalimab Injection” · registered Aug 2025
  • NCT05955105 · Innolake Biopharm · Phase 2 · live · background · “Toripalimab” · registered Jul 2023
RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024)33 studies
sacituzumab govitecanRecent, repeated
Evidence
  • NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Sacituzumab Govitecan for Injection” · registered Mar 2026
  • NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Sacituzumab Govitecan-hziy” · registered Apr 2023
  • NCT05113966 · Pharmacosmos A/S · Phase 2 · background · “Sacituzumab Govitecan-hziy” · registered Oct 2021
  • NCT05008510 · Veru Inc. · Phase 2 · comparator · “Sacituzumab Govitecan-hziy” · registered Aug 2021
  • NCT04927884 · ImmunityBio, Inc. · Phase 2 · background · “Sacituzumab Govitecan-Hziy” · registered Jun 2021
Gilead Sciences77% of its industry studiesUS: IMMUNOMEDICS INC (FDA 2020)EU: Gilead Sciences (EMA 2021)22 studies
VinorelbineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07533123 · Alphamab Oncology · Phase 3 · live · comparator · “Vinorelbine Tartrate Injection” · registered Mar 2026
  • NCT06519370 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Vinorelbine” · registered Jul 2024
  • NCT02555657 · Merck & Co., Inc · Phase 3 · comparator · “vinorelbine” · registered Sep 2015
  • NCT02225470 · Eisai Co., Ltd. · Phase 3 · comparator · “Vinorelbine injection” · registered Aug 2014
Eli Lilly and Company9% of its industry studies22 studies
IpilimumabRecent, repeated
Evidence
  • NCT07762703 · BreakBio Corp · Phase 2 · live · background · “Ipilimumab 2.5 mg” · registered Aug 2026
  • NCT05933265 · Lantern Pharma Inc. · Phase 2 · live · background · “Nivolumab & Ipilimumab” · registered Jun 2023
  • NCT03241173 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Aug 2017
  • NCT03126110 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Apr 2017
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)22 studies
olaparibRecent, repeated
Evidence
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Olaparib” · registered May 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Olaparib (if approved/available locally)” · registered Feb 2025
  • NCT05933265 · Lantern Pharma Inc. · Phase 2 · live · background · “Olaparib” · registered Jun 2023
AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014)23 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT07556848 · Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 3 · live · comparator · “Chemotherapy” · registered Apr 2026
  • NCT07108309 · Biocad · Phase 2 · live · background · “Chemotherapy” · registered Aug 2025
—22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Cyclophosphamide” · registered May 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Cyclophosphamide” · registered Feb 2025
  • NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
  • NCT05112536 · Pharmacosmos A/S · Phase 2 · background · “Cylophosphamide” · registered Oct 2021
  • NCT04927884 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Jun 2021
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed23 studies

25 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
ivonescimab☆ Track1 live phase-3 study: NCT06767527Akeso
sacituzumab govitecanApproved: US 2020 · EU 2021☆ Track3 live phase-3 studies: NCT05633654, NCT05382299, NCT05382286Gilead Sciences
Anti-TROP2 Antibody-drug Conjugate ESG401☆ Track1 live phase-3 study: NCT06732323Qilu Pharmaceutical Co., Ltd.
bulumtatug fuvedotin☆ Track1 live phase-3 study: NCT07556848Mabwell (Shanghai) Bioscience Co., Ltd.
trastuzumab rezetecan☆ Track2 live phase-3 studies: NCT07679360, NCT07111832Jiangsu HengRui Medicine Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 63 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (14)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.izalontamab brengitecan · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 main aimNCT06471205 A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer — primary endpoint: Objective Response Rate (ORR) · 52 enrolled
  • Dec 2026 est.ivonescimab · Akeso · Phase 3 main aimadded to Albumin-Bound PaclitaxelNCT06767527 AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer — primary endpoint: PFS assessed by IRRC · 416 enrolled
  • 30 Dec 2026 est.ivonescimab · Akeso · Phase 2 main aimadded to Albumin-Bound Paclitaxeladded to PaclitaxelNCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer — primary endpoint: Objective response rates (ORR) · 120 enrolled

11 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Triple Negative Breast Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 78 open · Antimitotic agents 27 open · Antibody-drug conjugates (ADCs) 26 open · Tyrosine kinase inhibitors (TKIs) 16 open · PARP inhibitors 14 open

Coming up

186studies finish main data collection within a year10 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 330 Triple Negative Breast Neoplasms studies recruiting now, 230 (70%) set no upper age limit and 85 (26%) stop at 75 or younger. 12 (4%) take children under 18. 106 (32%) are for women only and 0 (0%) for men only; 6 (2%) take healthy volunteers.

Recruiting studies that take each age, of 330
AgeWomenMen
106 (2%)5 (2%)
18321 (97%)217 (66%)
30327 (99%)222 (67%)
40329 (100%)223 (68%)
50329 (100%)223 (68%)
65328 (99%)222 (67%)
75282 (85%)212 (64%)
85239 (72%)191 (58%)

Across all 1,219 studies, recruiting or not: 19% stop at 75 or younger and 2% at 65; 2% take children; 37% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Triple Negative Breast Neoplasms studies take

Of 255 phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 59 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 154 mo35–80 · 209 studies53 mo32–70 · 136 studies58 mo37–96 · 73 studies
Phase 1/256 mo44–79 · 118 studies54 mo44–77 · 70 studies—
Phase 259 mo37–94 · 255 studies—60 mo38–99 · 220 studies
Phase 365 mo39–103 · 60 studies——
Interventional, no phase82 mo36–… · 49 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,219. Browse all 1,219 → or search them.